CHATTANOOGA, Tenn., May 6, 2013 /PRNewswire/ --Gold Bond® has been the gold standard for beating the heat and staying cool and dry for generations. Now, Chattem, Inc., the Consumer Healthcare Division of Sanofi US is introducing the same trusted brand in a new, no mess powder spray that delivers the odor and wetness protection of Gold Bond Powder in a convenient, easy-to-use spray.
(Photo: http://photos.prnewswire.com/prnh/20130506/CG03735)
The continuous spray delivers right where you want it - with a targeted stream different from the traditional powder. So whether you're looking to stay cool and dry for peak performance, or you just want to relieve and protect against odor, you can count on Gold Bond's triple action formula. Afterall, it's provided relief since 1908.
"The new Gold Bond No Mess Powder Spray is the same formula as Gold Bond Powder, and the new product packaging -- an easy-to-hold spray can with a 360 degree continuous spray top -- allows people to use it in an even more effective way," said John Stroud, Executive Vice President, Chattem.
The product is now available in drug, grocery and mass merchandise stores nationwide.
Gold Bond No Mess Powder Spray Fast Facts:
- Product benefits: Delivers the odor and wetness relief of Gold Bond Powder in a convenient, easy-to-use spray. The product provides triple action relief, cools on contact, absorbs moisture and soothes skin.
- When/How to Use: After shower, bath or exercise or whenever you want to stay cool and dry, simply use Gold Bond No Mess Powder Spray for lasting deodorant protection and that cool, refreshing feeling.
- Who Uses: People who want to stay comfortable while being active and people engaging in outdoor activities: sports, work, hiking, music festivals, summer sports camps, military, etc.
- Product ingredients: Talc, starch, zinc oxide, fragrance, cooling and soothing agents, and botanicals.
- Available in Two Formulas:
- Classic: Captures the feel, relief and scent of the original, classic medicated powder.
- Fresh: An update on the classic. Same feel and relief, but with a light, fresh fragrance.
- Size: 7 oz, 360 degree spray
- Suggested Retail Price/Availability: $7.99; on shelves next to Gold Bond Powder at major retailers including Wal-Mart, Target and Walgreens.
About Gold Bond
Powerful, hard-working and trusted since 1908, Gold Bond is now in its second century of healing. Gold Bond offers a broad line of products, including some of the fastest growing hand and body lotions, as well as the top selling medicated body powder, foot powder, foot cream, and foot pain cream in America. For more information, visit Gold Bond on Facebook and Twitter.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.
About Chattem
In March 2010, Chattem, Inc. became a wholly-owned subsidiary of the sanofi-aventis Group as the consumer healthcare division of Sanofi US. Chattem is more than 130 years old and is a leading manufacturer and marketer of branded consumer healthcare products, toiletries and dietary supplements across niche market segments in the United States. For more information, please visit Chattem's website at www.chattem.com.
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Contacts:
Media Relations
Rachel Ferrand
Tel.: 908 981 6673
Rachel.ferrand@sanofi.com
SOURCE Gold Bond
